Wall Street analysts forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will announce earnings per share of ($0.13) for the current quarter, according to Zacks. Two analysts have provided estimates for Sangamo Therapeutics’ earnings. The highest EPS estimate is $0.07 and the lowest is ($0.24). Sangamo Therapeutics posted earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.3%. The firm is expected to announce its next earnings results on Thursday, November 8th.
On average, analysts expect that Sangamo Therapeutics will report full-year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.42). For the next year, analysts anticipate that the business will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.06) to ($0.44). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. During the same period in the prior year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 159.6% compared to the same quarter last year.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $15.67, for a total transaction of $78,350.00. Following the sale, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at $191,957.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock worth $458,750 over the last ninety days. Company insiders own 1.20% of the company’s stock.
Several large investors have recently bought and sold shares of SGMO. Riverhead Capital Management LLC raised its stake in shares of Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,667 shares during the last quarter. Mount Yale Investment Advisors LLC raised its stake in shares of Sangamo Therapeutics by 2,202.8% in the second quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 7,996 shares during the last quarter. NumerixS Investment Technologies Inc bought a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $125,000. Tyers Asset Management LLC raised its stake in shares of Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 7,232 shares during the last quarter. Finally, First Mercantile Trust Co. raised its stake in shares of Sangamo Therapeutics by 93.7% in the first quarter. First Mercantile Trust Co. now owns 7,666 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 3,708 shares during the last quarter. Institutional investors own 63.95% of the company’s stock.
SGMO stock traded up $0.50 during trading on Wednesday, reaching $15.80. 57,800 shares of the stock were exchanged, compared to its average volume of 2,034,642. Sangamo Therapeutics has a twelve month low of $10.40 and a twelve month high of $27.50. The company has a market cap of $1.56 billion, a PE ratio of -21.86 and a beta of 2.74. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.07.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Further Reading: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.